Axon Enterprise, INC

Axon Enterprise, Inc. announced the immediate appointment of Vivek Mohindra and Eiso Kant to its Board of Directors, effective July 8, 2026.

Axon Enterprise, Inc. reported on its 2026 Annual Meeting of Shareholders, detailing director elections, executive compensation advisory vote, and ratification of its independent auditor.

Axon Enterprise announced record Q1 2026 revenue of $807 million, a 34% year-over-year increase, driven by robust demand across its product ecosystem and a raised full-year revenue outlook.

Axon Enterprise, Inc. announced that director Matthew McBrady will not stand for re-election at the upcoming 2026 Annual Meeting of Shareholders.

Axon Enterprise, Inc. announced Q4 2025 revenue of $797 million, a 39% year-over-year increase, and established new 2028 targets including $6 billion in annual revenue.

Axon Enterprise, Inc. announced the full redemption and conversion of its 0.50% convertible senior notes due 2027, eliminating all outstanding debt of this type.

Axon Enterprise, Inc. reported a net loss of $2.2 million for the third quarter of 2025 despite a 30.6% increase in net sales, driven by higher operating expenses and interest costs, while announcing significant acquisitions.

Axon Enterprise, Inc. reported robust revenue growth for Q2 2025, but shifted to an operating loss and saw net income decline, driven by increased operating expenses and interest costs.

Axon Enterprise's Q1 2025 shows strong revenue growth driven by both Connected Devices and Software & Services, with strategic investment gains offsetting increased operating expenses and debt-related costs.

Axon Enterprise's Q3 2024 results show a significant revenue increase, though operating expenses also rose, impacting overall profitability.

Axon Enterprise's Q2 2024 results show a significant revenue increase driven by strong performance in both its TASER and Software and Sensors segments, though operating income saw a slight decrease.

Axon Enterprise's Q1 2024 results show a significant increase in revenue, driven by strong growth in its Software and Sensors segment, despite a decrease in gross margin percentage.

Axon Enterprise, Inc. reported a 33.5% increase in net sales to $2.8 billion for 2025, but net income significantly decreased to $124.7 million from $377.0 million in the prior year, alongside a material weakness in internal controls.

Axon Enterprise files an amended 10-K/A to restate prior financial statements due to an error in classifying convertible senior notes and discloses an additional material weakness in internal controls.

Axon Enterprise's 2024 10-K filing reveals a 33.4% increase in revenue alongside the identification of a material weakness in internal controls related to revenue recognition.

Axon Enterprise's 10-K filing details the company's registered common stock, preferred stock authorization, and various corporate governance and anti-takeover provisions.

Axon Enterprise Director Eiso Kant acquired 600 shares of common stock through a restricted stock unit grant.

Axon Enterprise Director Vivek Mohindra acquired 600 time-vested restricted stock units under the company's 2022 Stock Incentive Plan.

Axon Enterprise CEO Patrick W. Smith has sold a significant number of company shares through a pre-arranged trading plan, as disclosed in a Form 4 filing.

Axon Enterprise CEO Patrick W. Smith reported the sale of 10,000 shares of common stock, valued at approximately $5 million, executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise President Joshua Isner sold 12,661 shares of common stock on June 5, 2026.

Elizabeth Reid Coughlin, Chief Human Officer of Axon Enterprise, Inc., sold 1,554 shares of common stock.

Axon Enterprise reports record 2025 revenue of $2.8 billion and outlines its AI-driven growth strategy in its 2026 proxy statement.

Axon's Compensation Committee provides supplemental context to its proxy materials, highlighting the incorporation of shareholder feedback into executive compensation structures.

Axon Enterprise restated its financial statements for fiscal year 2024 and the first three quarters of 2024 due to a balance sheet presentation error related to convertible senior notes, but a subsequent review determined that no executive compensation clawback was necessary.

Axon Enterprise's upcoming annual meeting on May 29, 2025, will address the election of directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the company's auditor.

Axon Enterprise achieved record revenue of $2.1 billion in 2024, marking its third consecutive year of 30%+ revenue growth and demonstrating strong execution in the public safety technology sector.

Axon Enterprise, Inc. distributed a letter on April 15, 2024, as part of its definitive proxy statement filing.

Axon Enterprise, Inc. filed its quarterly Form 13F, disclosing its investment holdings as of March 31, 2026, with a total reported value of $18,051,979.

Axon Enterprise, Inc. has filed its Q3 2025 13F-HR report, revealing a significant holding of 3.68 million ordinary shares in Cellebrite DI Ltd valued at over $68 million.

Axon Enterprise, Inc. reported its Q2 2025 institutional holdings, revealing a significant stake in Cellebrite DI Ltd. ordinary shares.

Axon Enterprise, Inc. reports holding $174.87 million in Cellebrite DI Ltd. as of March 31, 2025.

Axon Enterprise, Inc. reports holding $198.3 million in Cellebrite DI Ltd. Ordinary Shares as of December 31, 2024.

Vanguard Capital Management has reported a beneficial ownership of 7.23% in Axon Enterprise Inc. common stock as of March 31, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Axon Enterprise Inc., totaling 7,486,272 shares of common stock.

The Vanguard Group has filed an Amendment No. 11 to its Schedule 13G, disclosing a continued beneficial ownership of 11.86% in Axon Enterprise Inc.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.2% of Axon Enterprise Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.7% beneficial ownership stake in Axon Enterprise Inc. as of December 31, 2024.